For example, p53 pathway inactivation is common in high grade serous ovarian carcinomas, KRAS is implicated in mucinous and low grade serous ovarian carcinomas, and mismatch repair deficiency is involved in endometrioid ovarian carcinomas [49]. This evidence concerns the gene KRAS and ovarian serous carcinoma.